Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma

Sponsor
Cancer Research UK
Study ID
NCT00974792
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

  • pegfilgrastim — BIOLOGICAL
  • rituximab — BIOLOGICAL
  • cyclophosphamide — DRUG
  • cytarabine — DRUG
  • doxorubicin hydrochloride — DRUG
  • etoposide phosphate — DRUG
  • ifosfamide — DRUG
  • leucovorin calcium — DRUG
  • methotrexate — DRUG
  • vincristine sulfate — DRUG

Study Details

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer cell growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cell-killing substances to them. Giving more than one drug (combination chemotherapy) together with rituximab may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving combination chemotherapy together with rituximab works in treating patients with diffuse large B-cell non-Hodgkin lymphoma.

Key Dates

Start date
Jan 31, 2006
Status verified
Sep 2009
Primary completion
May 31, 2011

Study Design

Enrollment
150 participants (estimated)
Primary purpose
TREATMENT

Primary Outcome Measure

Complete response rate

Related Studies